Akebia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| (dollars in thousands, except per share amounts) | 2023 | 2022 |
| Revenues: | ||
| Product revenue, net | $170,301 | $176,949 |
| License, collaboration and other revenue | 24,322 | 115,535 |
| Total revenues | 194,623 | 292,484 |
| Cost of goods sold: | ||
| Cost of product and other revenue | 38,107 | 49,526 |
| Amortization of intangible asset | 36,042 | 36,042 |
| Total cost of goods sold | 74,149 | 85,568 |
| Operating expenses: | ||
| Research and development | 63,079 | 129,986 |
| Selling, general and administrative | 100,233 | 138,601 |
| License | 3,237 | 3,175 |
| Restructuring | 181 | 15,933 |
| Total operating expenses | 166,730 | 287,695 |
| Loss from operations | (46,256) | (80,779) |
| Other income (expense): | ||
| Interest expense | (6,032) | (15,687) |
| Other income | 887 | 3,146 |
| Loss on extinguishment of debt | — | (906) |
| Loss on termination of lease | (524) | — |
| Net loss before income taxes | (51,925) | (94,226) |
| Net loss | $(51,925) | $(94,226) |
| Comprehensive loss | $(51,925) | $(94,226) |
| Net loss per share: | ||
| Basic and diluted | $(0.28) | $(0.52) |
| Weighted average number of common shares outstanding: | ||
| Basic and diluted | 187,465,448 | 182,782,680 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.